Ultragenyx Pharmaceutical Inc. (RARE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US90400D1081
Ultragenyx Pharmaceutical Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 673.00 m USD |
| Operating income | -535.00 m USD |
| EBIT | -596.00 m USD |
| Net income | -575.00 m USD |
| Diluted EPS – continuing operations | -5.83 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
More stocks
- SELLAS Life Sciences Group, Inc. (SLS)
- Lotte Rental Co Ltd (089860.KS)
- Cymbria Corporation (CYB.TO)
- Zhejiang Jingxin Pharmaceutical Co Ltd (002020.SZ)
- Global Net Lease, Inc. (GNL)
- Shenzhen Colibri Technologies Co Ltd (002957.SZ)
- NETSTREIT Corp. (NTST)
- Youngone Holdi (009970.KS)
- HYCROFT MINING HOLDING CORP (HYMC)
- IQM Quantum Computers Oyj American Depositary Shares (IQMX)
- NovoCure Ltd (NVCR)
- Dom Development SA (DOM.WA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.